US 12,448,425 B2
Therapeutic peptides
Chun Li, Houston, TX (US); Chiyi Xiong, Houston, TX (US); Yunfei Wen, Houston, TX (US); and Anil Sood, Houston, TX (US)
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Appl. No. 17/609,536
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
PCT Filed May 8, 2020, PCT No. PCT/US2020/032074
§ 371(c)(1), (2) Date Nov. 8, 2021,
PCT Pub. No. WO2020/227620, PCT Pub. Date Nov. 12, 2020.
Claims priority of provisional application 62/844,986, filed on May 8, 2019.
Prior Publication US 2022/0213165 A1, Jul. 7, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 38/08 (2019.01); A61K 38/10 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61K 49/00 (2006.01); A61K 51/12 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/705 (2013.01) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); A61K 47/6415 (2017.08); A61K 47/6425 (2017.08); A61K 47/6909 (2017.08); A61K 49/0082 (2013.01); A61K 51/1227 (2013.01); A61P 35/00 (2018.01); A61K 38/00 (2013.01)] 38 Claims
 
1. A non-natural peptide comprising TNd (Y) LFSPNGPIARAW (SEQ ID NO:1) or a sequence that has 1, 2, 3, or 4 amino acid substitutions relative to SEQ ID NO: 1 and retains the D-amino acid at position 3 of SEQ ID NO:1.